IL238807A0 - pharmaceutical preparations - Google Patents
pharmaceutical preparationsInfo
- Publication number
- IL238807A0 IL238807A0 IL238807A IL23880715A IL238807A0 IL 238807 A0 IL238807 A0 IL 238807A0 IL 238807 A IL238807 A IL 238807A IL 23880715 A IL23880715 A IL 23880715A IL 238807 A0 IL238807 A0 IL 238807A0
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737177P | 2012-12-14 | 2012-12-14 | |
| PCT/US2013/075196 WO2014093941A1 (en) | 2012-12-14 | 2013-12-14 | Pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL238807A0 true IL238807A0 (en) | 2015-06-30 |
Family
ID=50935020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL238807A IL238807A0 (en) | 2012-12-14 | 2015-05-13 | pharmaceutical preparations |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9795619B2 (enExample) |
| EP (1) | EP2931285A4 (enExample) |
| JP (1) | JP2016503030A (enExample) |
| KR (1) | KR20150093819A (enExample) |
| CN (1) | CN104902905A (enExample) |
| AU (1) | AU2013358897B2 (enExample) |
| BR (1) | BR112015013695A2 (enExample) |
| CA (1) | CA2893959A1 (enExample) |
| CL (1) | CL2015001660A1 (enExample) |
| CR (1) | CR20150313A (enExample) |
| EA (1) | EA201590862A1 (enExample) |
| HK (1) | HK1209638A1 (enExample) |
| IL (1) | IL238807A0 (enExample) |
| MA (1) | MA38182A1 (enExample) |
| MX (1) | MX2015007563A (enExample) |
| PE (1) | PE20151326A1 (enExample) |
| PH (1) | PH12015501156A1 (enExample) |
| SG (2) | SG11201503807TA (enExample) |
| WO (1) | WO2014093941A1 (enExample) |
| ZA (1) | ZA201503594B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3387B1 (ar) | 2011-12-16 | 2019-03-13 | Glaxosmithkline Llc | مشتقات بيتولين |
| JP2016503030A (ja) * | 2012-12-14 | 2016-02-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 医薬組成物 |
| CA2893843C (en) | 2012-12-21 | 2018-09-04 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| US9637516B2 (en) | 2012-12-31 | 2017-05-02 | Hetero Research Foundation | Betulinic acid proline derivatives as HIV inhibitors |
| NO2865735T3 (enExample) | 2013-07-12 | 2018-07-21 | ||
| DK3019503T3 (da) | 2013-07-12 | 2017-11-20 | Gilead Sciences Inc | Polycykliske-carbamoylpyridon-forbindelser og anvendelse deraf til behandling af hiv-infektioner |
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| NO2717902T3 (enExample) | 2014-06-20 | 2018-06-23 | ||
| US20170129916A1 (en) | 2014-06-26 | 2017-05-11 | Hetero Research Foundation | Novel betulinic proline imidazole derivatives as hiv inhibitors |
| EP3197430A1 (en) * | 2014-09-26 | 2017-08-02 | Glaxosmithkline Intellectual Property (No. 2) Limited | Long acting pharmaceutical compositions |
| TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| MA40886B1 (fr) | 2015-02-09 | 2020-03-31 | Hetero Research Foundation | Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih |
| US10370405B2 (en) | 2015-03-16 | 2019-08-06 | Hetero Labs Limited | C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors |
| TR201905009T4 (tr) | 2015-04-02 | 2019-05-21 | Gilead Sciences Inc | Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları. |
| WO2018042332A1 (en) * | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
| WO2018042331A1 (en) * | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
| KR20260015342A (ko) | 2017-07-21 | 2026-02-02 | 비이브 헬쓰케어 컴퍼니 | Hib 감염 및 aids를 치료하기 위한 요법 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
| US5358721A (en) * | 1992-12-04 | 1994-10-25 | Alza Corporation | Antiviral therapy |
| EP1292562A1 (en) | 2000-05-23 | 2003-03-19 | Univerzita palackeho V Olomouci | Triterpenoid derivatives |
| WO2003011254A1 (en) * | 2001-07-31 | 2003-02-13 | Capricorn Pharma Inc. | Amorphous drug beads |
| US20080206161A1 (en) * | 2002-10-25 | 2008-08-28 | Dov Tamarkin | Quiescent foamable compositions, steroids, kits and uses thereof |
| US20050142205A1 (en) * | 2003-07-18 | 2005-06-30 | Julia Rashba-Step | Methods for encapsulating small spherical particles prepared by controlled phase separation |
| US20060019934A1 (en) * | 2004-05-20 | 2006-01-26 | Saxena Brij B | Anti-HIV-1 activity of betulinol derivatives |
| TW200628161A (en) | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
| CN1682740A (zh) * | 2005-03-11 | 2005-10-19 | 中国药科大学 | 五环三萜类化合物在制备糖原磷酸化酶抑制剂中的应用 |
| WO2006105356A2 (en) | 2005-03-29 | 2006-10-05 | Regents Of The University Of Minnesota | Methods of manufacturing bioactive 3-esters of betulinic aldehyde and betulinic acid |
| TWI457136B (zh) | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Ｈｉｖ-感染之預防 |
| WO2006117666A2 (en) * | 2005-04-29 | 2006-11-09 | Pfizer Inc. | Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery |
| US20070197646A1 (en) | 2006-02-21 | 2007-08-23 | Achillion Pharmaceuticals, Inc. | Substituted taraxastanes useful for treating viral infections |
| FI121468B (fi) * | 2006-06-07 | 2010-11-30 | Valtion Teknillinen | Betuliiniperäiset yhdisteet antimikrobisina aineina |
| PT2040671T (pt) | 2006-06-23 | 2018-03-14 | Janssen Sciences Ireland Uc | Suspensões aquosas de tmc278 |
| WO2008127364A2 (en) | 2006-10-13 | 2008-10-23 | Myriad Genetics, Inc. | Antiviral compounds and use thereof |
| TW200837074A (en) * | 2006-11-03 | 2008-09-16 | Panacos Pharmaceuticals Inc | Extended triterpene derivatives |
| US8426434B2 (en) * | 2007-07-12 | 2013-04-23 | Tibotec Pharmaceuticals Ltd. | Crystalline form of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile |
| EP2240504A1 (en) * | 2008-01-03 | 2010-10-20 | Virochem Pharma Inc. | Novel c-21-keto lupane derivatives preparation and use thereof |
| EP2250185A4 (en) | 2008-01-03 | 2011-11-16 | Virochem Pharma Inc | NEW LUPANDERIVATE |
| DE102008037025C5 (de) * | 2008-08-08 | 2016-07-07 | Jesalis Pharma Gmbh | Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform |
| WO2010053817A1 (en) | 2008-11-04 | 2010-05-14 | Trustees Of Dartmouth College | Betulinic acid derivatives and methods of use thereof |
| CZ301318B6 (cs) | 2008-11-13 | 2010-01-13 | Univerzita Palackého v Olomouci | 2-Deoxyglykosidy triterpenoidu, zpusob jejich prípravy a jejich použití jako lécivo |
| KR101733625B1 (ko) * | 2008-12-11 | 2017-05-10 | 시오노기세야쿠 가부시키가이샤 | 카르바모일피리돈 ｈｉｖ 인테그라제 억제제 및 중간체의 합성 |
| US8802727B2 (en) | 2009-07-14 | 2014-08-12 | Hetero Research Foundation, Hetero Drugs Limited | Pharmaceutically acceptable salts of betulinic acid derivatives |
| US9067966B2 (en) | 2009-07-14 | 2015-06-30 | Hetero Research Foundation, Hetero Drugs Ltd. | Lupeol-type triterpene derivatives as antivirals |
| JP2013519674A (ja) * | 2010-02-11 | 2013-05-30 | グラクソスミスクライン エルエルシー | ベツリンの誘導体 |
| TWI577377B (zh) | 2010-09-16 | 2017-04-11 | Ｖｉｉｖ醫療保健公司 | 醫藥組合物 |
| WO2013020246A1 (en) | 2011-08-08 | 2013-02-14 | Glaxosmithkline Llc | Methylene derivatives of betulin |
| WO2013020245A1 (en) | 2011-08-08 | 2013-02-14 | Glaxosmithkline Llc | Carbonyl derivatives of betulin |
| EP2791102B1 (en) | 2011-12-14 | 2016-05-18 | Glaxosmithkline LLC | Propenoate derivatives of betulin |
| JO3387B1 (ar) | 2011-12-16 | 2019-03-13 | Glaxosmithkline Llc | مشتقات بيتولين |
| WO2014035945A1 (en) | 2012-08-28 | 2014-03-06 | Glaxosmithkline Llc | Pharmaceutical compositions |
| JP2016503030A (ja) * | 2012-12-14 | 2016-02-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 医薬組成物 |
| EP3197430A1 (en) | 2014-09-26 | 2017-08-02 | Glaxosmithkline Intellectual Property (No. 2) Limited | Long acting pharmaceutical compositions |
-
2013
- 2013-12-14 JP JP2015548025A patent/JP2016503030A/ja active Pending
- 2013-12-14 CA CA2893959A patent/CA2893959A1/en not_active Abandoned
- 2013-12-14 SG SG11201503807TA patent/SG11201503807TA/en unknown
- 2013-12-14 PE PE2015000924A patent/PE20151326A1/es not_active Application Discontinuation
- 2013-12-14 EA EA201590862A patent/EA201590862A1/ru unknown
- 2013-12-14 AU AU2013358897A patent/AU2013358897B2/en not_active Ceased
- 2013-12-14 KR KR1020157018488A patent/KR20150093819A/ko not_active Withdrawn
- 2013-12-14 SG SG10201704467SA patent/SG10201704467SA/en unknown
- 2013-12-14 HK HK15110448.0A patent/HK1209638A1/xx unknown
- 2013-12-14 EP EP13863026.4A patent/EP2931285A4/en not_active Withdrawn
- 2013-12-14 WO PCT/US2013/075196 patent/WO2014093941A1/en not_active Ceased
- 2013-12-14 BR BR112015013695A patent/BR112015013695A2/pt not_active IP Right Cessation
- 2013-12-14 MX MX2015007563A patent/MX2015007563A/es unknown
- 2013-12-14 US US14/651,673 patent/US9795619B2/en not_active Expired - Fee Related
- 2013-12-14 CN CN201380065306.9A patent/CN104902905A/zh active Pending
- 2013-12-14 MA MA38182A patent/MA38182A1/fr unknown
-
2015
- 2015-05-13 IL IL238807A patent/IL238807A0/en unknown
- 2015-05-21 ZA ZA2015/03594A patent/ZA201503594B/en unknown
- 2015-05-25 PH PH12015501156A patent/PH12015501156A1/en unknown
- 2015-06-12 CR CR20150313A patent/CR20150313A/es unknown
- 2015-06-12 CL CL2015001660A patent/CL2015001660A1/es unknown
-
2017
- 2017-10-19 US US15/787,987 patent/US20180042944A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2931285A1 (en) | 2015-10-21 |
| MA38182A1 (fr) | 2018-04-30 |
| AU2013358897B2 (en) | 2017-01-05 |
| ZA201503594B (en) | 2018-11-28 |
| SG11201503807TA (en) | 2015-06-29 |
| KR20150093819A (ko) | 2015-08-18 |
| PE20151326A1 (es) | 2015-10-12 |
| CN104902905A (zh) | 2015-09-09 |
| US20180042944A1 (en) | 2018-02-15 |
| WO2014093941A1 (en) | 2014-06-19 |
| PH12015501156A1 (en) | 2015-08-10 |
| US9795619B2 (en) | 2017-10-24 |
| CL2015001660A1 (es) | 2015-10-02 |
| CA2893959A1 (en) | 2014-06-19 |
| HK1209638A1 (en) | 2016-04-08 |
| EA201590862A1 (ru) | 2016-05-31 |
| SG10201704467SA (en) | 2017-06-29 |
| US20150313917A1 (en) | 2015-11-05 |
| AU2013358897A1 (en) | 2015-07-02 |
| CR20150313A (es) | 2015-10-19 |
| EP2931285A4 (en) | 2016-06-01 |
| BR112015013695A2 (pt) | 2017-07-11 |
| JP2016503030A (ja) | 2016-02-01 |
| MX2015007563A (es) | 2015-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286348A (en) | Pharmaceutical preparations that include allopregnanolone | |
| ZA201703992B (en) | Inhalable pharmaceutical compositions | |
| GB201113662D0 (en) | Pharmaceutical compositions | |
| ZA201503594B (en) | Pharmaceutical compositions | |
| AP3656A (en) | Pharmaceutical compositions | |
| ZA201501930B (en) | Pharmaceutical composition | |
| ZA201308208B (en) | Pharmaceutical compositions | |
| ZA201407373B (en) | Novel pharmaceutical formulations | |
| EP2832730A4 (en) | MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION | |
| SG11201403943TA (en) | Chitosan-derived compositions | |
| IL266415A (en) | Innovative pharmaceutical composition | |
| GB201201287D0 (en) | Compositions | |
| GB201118181D0 (en) | Pharmaceutical compositions | |
| ZA201502987B (en) | Pharmaceutical composition | |
| GB201211153D0 (en) | Pharmaceutical compositions | |
| IL238075A0 (en) | pharmaceutical preparations | |
| GB201219234D0 (en) | Pharmaceutical compositions | |
| GB201213303D0 (en) | Pharmaceutical compositions | |
| GB201204810D0 (en) | Pharmaceutical compositions | |
| ZA201400751B (en) | Pharmaceutical composition | |
| GB201221130D0 (en) | New pharmaceutical composition | |
| GB201207628D0 (en) | New pharmaceutical composition | |
| GB201207701D0 (en) | New pharmaceutical composition | |
| GB201211403D0 (en) | Pharmaceutical formulations | |
| GB201211406D0 (en) | Pharmaceutical formulations |